Interventional Cardiology Devices and Equipment Market Report 2026

The interventional cardiology devices and equipment market size has grown strongly in recent years. It will grow from $15.65 billion in 2025 to $16.46 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increased adoption of minimally invasive procedures, expansion of cardiac catheterization laboratories, improvements in stent and catheter materials, growing aging population.

The interventional cardiology devices and equipment market size is expected to see strong growth in the next few years. It will grow to $21.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for next-generation interventional devices, rising adoption of AI-assisted cardiac procedures, expansion of outpatient and ambulatory cardiac care, growing focus on patient-specific therapies, increasing investments in cardiovascular innovation. Major trends in the forecast period include increasing adoption of drug-eluting and bioabsorbable stents, rising use of advanced catheter-based therapies, growing integration of imaging-guided interventions, expansion of minimally invasive cardiac procedures, enhanced focus on precision and patient safety.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the interventional cardiology devices and equipment market. Cardiovascular diseases encompass a range of health issues related to the blood vessels, circulatory system, and heart. These conditions are increasing due to factors such as poor diets, lack of physical activity, stress, smoking, and obesity. As the incidence of cardiovascular diseases rises, the demand for interventional cardiology devices grows, as more heart patients require advanced tools for minimally invasive treatments. For example, in October 2025, the Australian Institute of Health and Welfare, an Australian government agency, reported that cardiovascular disease accounted for nearly 12% of the total disease burden in Australia in 2024, with 14% for males and 10% for females. Australians lost an estimated 685,000 years of healthy life due to all forms of cardiovascular disease, equivalent to 25.5 years per 1,000 population. As such, the increasing incidence of cardiovascular diseases is expected to drive the growth of the interventional cardiology devices and equipment market.

Leading companies operating in the interventional cardiology devices and equipment market are focusing on developing innovative technological products to meet the growing demand for minimally invasive procedures in the treatment of cardiovascular diseases. For instance, in February 2023, SIS Medical AG, a Switzerland-based medical company, introduced the OPN NC percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter with Twin-Wall technology. This next-generation balloon catheter is designed to deliver superior performance when treating challenging coronary lesions. The OPN NC percutaneous transluminal coronary angioplasty (PTCA) catheter holds the potential to enhance the outcomes of patients with coronary artery disease.

In March 2025, Boston Scientific, a US-based medical device company, acquired SoniVie Ltd. for approximately $540 million. This acquisition aims to enhance Boston Scientific's interventional cardiology therapy portfolio by integrating SoniVie's TIVUS Intravascular Ultrasound System, an investigational ultrasound-based renal denervation technology designed to treat hypertensive disorders. SoniVie, an Israel-based company, specializes in investigational intravascular ultrasound systems focused on nerve ablation for renal denervation.

Major companies operating in the interventional cardiology devices and equipment market are GE Healthcare, Abbott Laboratories, Boston Scientific Corporation, Medtronic Inc., Johnson & Johnson, B. Braun Melsungen AG, Biosensors International Ltd, Cook Medical LLC, Biotronik SE & Co. KG, ACIST Medical Systems Inc., Cordis Corporation, Terumo Corporation, Cardinal Health Inc., iVascular GmbH, Teleflex Incorporated, Merit Medical Systems Inc., MicroPort Scientific Corporation, Asahi Intecc Co. Ltd., AngioDynamics, C. R. Bard Inc., Endologix Inc., Lombard Medical Limited, Spectranetics Corporation, Vascular Solutions Inc., W. L. Gore & Associates Inc., Cardiva Medical Inc., Cardiovascular Systems Inc., ClearStream Technologies Ltd., Contego Medical LLC, Shockwave Medical Inc.

North America was the largest region in the global interventional cardiology devices and equipment market in 2025. Western Europe was the second-largest region in the interventional cardiology devices and equipment market. The regions covered in the interventional cardiology devices and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional cardiology devices and equipment market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs are impacting the interventional cardiology devices and equipment market by increasing costs of imported specialty metals, polymers, coatings, electronic components, and precision manufacturing tools used in stents, catheters, and guidewires. Hospitals and device manufacturers in North America and Europe are most affected due to reliance on globally sourced components, while Asia-Pacific faces pricing pressure on export-oriented device production. These tariffs are elevating device prices and influencing procurement budgets for cardiac care providers. However, they are also encouraging localized manufacturing, regional supplier partnerships, and increased investment in domestic production capabilities for critical cardiovascular devices.

The interventional cardiology devices and equipment market research report is one of a series of new reports that provides interventional cardiology devices and equipment market statistics, including interventional cardiology devices and equipment industry global market size, regional shares, competitors with a interventional cardiology devices and equipment market share, detailed interventional cardiology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the interventional cardiology devices and equipment industry. This interventional cardiology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interventional cardiology devices and equipment are essential tools used within the field of interventional cardiology, which focuses on treating structural heart diseases through catheter-based procedures.

The primary categories of interventional cardiology devices and equipment encompass angioplasty balloons, angioplasty stents, catheters, plaque modification devices, and other specialized interventional cardiology instruments. Catheters are flexible, tubular medical devices designed for insertion into canals, vessels, passageways, or body cavities to facilitate the injection or withdrawal of fluids or to maintain the passage's patency. The market is further segmented by age group, including newborns (0-30 days), infants (31 days to 1 year), children (1-18 years), and adults (18+ years). These devices find applications across a variety of settings, such as hospitals, clinics, cardiac catheterization labs, and ambulatory surgical centers.

The interventional cardiology devices and equipment market consists of sales of equipment with technologies such as vascular closure, atherectomy, intravascular ultrasound, fractional flow reserve, and optical coherence tomography (OCT) that are used for the treatment of interventional structural heart diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.